NCT00089037View on ClinicalTrials.gov

Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2003

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
Interventions
DRUG

methotrexate

DRUG

sirolimus

DRUG

tacrolimus

Trial Locations (1)

98109-1024

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00089037 - Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation | Biotech Hunter | Biotech Hunter